Non-alcoholic fatty liver disease: the pathologist’s perspective

키워드

참고문헌 (96)

1. European Association for the Study of the Liver(EASL), "EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease", J Hepatol, 64, pp.1388~1402 (2016)
2. 강성희, "KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease", Clinical and Molecular Hepatology, 27(3), pp.363~401 (2021), 대한간학회
3. Chalasani N, "The diagnosis and management of nonalcoholic fatty liver disease : practice guidance from the American Association for the Study of Liver Diseases", Hepatology, 67, pp.328~357 (2018)
4. Brunt EM, "Histopathology of nonalcoholic fatty liver disease", World J Gastroenterol, 16, pp.5286~5296 (2010)
5. Sheka AC, "Nonalcoholic steatohepatitis : a review", JAMA, 323, pp.1175~1183 (2020)
6. Takahashi Y, "Histopathology of nonalcoholic fatty liver disease", nonalcoholic steatohepatitis, 2014, pp.20, 15539~15548
7. Kleiner DE, "Design and validation of a histological scoring system for nonalcoholic fatty liver disease", Hepatology, 41, pp.1313~1321 (2005)
8. Chalasani N, "Relationship of steatosis grade and zonal location to histological features of steatohepatitis in adult patients with non-alcoholic fatty liver disease", J Hepatol, 48, pp.829~834 (2008)
9. Caldwell S, "Hepatocellular ballooning in NASH", J Hepatol, 53, pp.719~723 (2010)
10. Machado MV, "Cell death and nonalcoholic steatohepatitis : where is ballooning relevant?", Expert Rev Gastroenterol Hepatol, 5, pp.213~222 (2011)
11. Li MK, "The pathology of cholestasis", Semin Liver Dis, 24, pp.21~42 (2004)
12. Ibrahim SH, "Non-alcoholic steatohepatitis pathogenesis : sublethal hepatocyte injury as a driver of liver inflammation", Gut, 67, pp.963~972 (2018)
13. Hirsova P, "Ballooned hepatocytes, undead cells, sonic hedgehog, and vitamin E : therapeutic implications for nonalcoholic steatohepatitis", Hepatology, 61, pp.15~17 (2015)
14. Rangwala F, "Increased production of sonic hedgehog by ballooned hepatocytes", J Pathol, 224, pp.401~410 (2011)
15. Sookoian S, "Heat shock protein 27 is down-regulated in ballooned hepatocytes of patients with nonalcoholic steatohepatitis(NASH)", Sci Rep, 6, pp.22528~ (2016)
16. Verdelho Machado M, "The hedgehog pathway in nonalcoholic fatty liver disease", Crit Rev Biochem Mol Biol, 53, pp.264~278 (2018)
17. Guy CD, "Treatment response in the PIVENS trial is associated with decreased hedgehog pathway activity", Hepatology, 61, pp.98~107 (2015)
18. Lackner C, "Ballooned hepatocytes in steatohepatitis : the value of keratin immunohistochemistry for diagnosis", J Hepatol, 48, pp.821~828 (2008)
19. Zatloukal K, "From mallory to mallory-denk bodies: what, how and why?", Exp Cell Res, 313, pp.2033~2049 (2007)
20. Zatloukal K, "The keratin cytoskeleton in liver diseases", J Pathol, 204, pp.367~376 (2004)
21. Guy CD, "Costaining for keratins 8", 18 plus ubiquitin improves detection of hepatocyte injury in nonalcoholic fatty liver disease, 2012, pp.43, 790~800
22. Denk H, "Mallory bodies revisited", J Hepatol, 32, pp.689~702 (2000)
23. Matteoni CA, "Nonalcoholic fatty liver disease : a spectrum of clinical and pathological severity", Gastroenterology, 116, pp.1413~1419 (1999)
24. Feldstein AE, "Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis", Gastroenterology, 125, pp.437~443 (2003)
25. Yeh MM, "Pathological features of fatty liver disease", Gastroenterology, 147, pp.754~764 (2014)
26. Straub BK, "Pathology and biopsy assessment of non-alcoholic fatty liver disease", Dig Dis, 28, pp.197~202 (2010)
27. Brunt EM, "Portal chronic inflammation in nonalcoholic fatty liver disease(NAFLD) : a histologic marker of advanced NAFLD-clinicopathologic correlations from the nonalcoholic steatohepatitis clinical research network", Hepatology, 49, pp.809~820 (2009)
28. Neuschwander-Tetri BA, "Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone", Hepatology, 38, pp.1008~1017 (2003)
29. Kim JK, "Transitional features of histologic type of non-alcoholic fatty liver disease in Korean young men", J Gastroenterol Hepatol, 27, pp.142~148 (2012)
30. Brunt EM, "Concurrence of histologic features of steatohepatitis with other forms of chronic liver disease", Mod Pathol, 16, pp.49~56 (2003)
31. Schwabe RF, "Mechanisms of fibrosis development in nonalcoholic steatohepatitis", Gastroenterology, 158, pp.1913~1928 (2020)
32. Brunt EM, "Nonalcoholic steatohepatitis : a proposal for grading and staging the histological lesions", Am J Gastroenterol, 94, pp.2467~2474 (1999)
33. Friedman SL, "Mechanisms of NAFLD development and therapeutic strategies", Nat Med, 24, pp.908~922 (2018)
34. Sanyal AJ, "Nonalcoholic steatohepatitis : association of insulin resistance and mitochondrial abnormalities", Gastroenterology, 120, pp.1183~1192 (2001)
35. Nobili V, "NAFLD in children : new genes, new diagnostic modalities and new drugs", Nat Rev Gastroenterol Hepatol, 16, pp.517~530 (2019)
36. Schwimmer JB, "Histopathology of pediatric nonalcoholic fatty liver disease", Hepatology, 42, pp.641~649 (2005)
37. Chan AW, "Atlas of Liver Pathology", pp.11~12, Springer
38. Calvaruso V, "Computer-assisted image analysis of liver collagen : relationship to Ishak scoring and hepatic venous pressure gradient", Hepatology, 49, pp.1236~1244 (2009)
39. Huang Y, "Image analysis of liver collagen using sirius red is more accurate and correlates better with serum fibrosis markers than trichrome", Liver Int, 33, pp.1249~1256 (2013)
40. Campos CF, "An inexpensive and worldwide available digital image analysis technique for histological fibrosis quantification in chronic hepatitis C", J Viral Hepat, 21, pp.216~222 (2014)
41. Vyberg M, "Detection of early zone 3 liver fibrosis in chronic alcoholics. a comparison of four connective tissue staining methods", Acta Pathol Microbiol Immunol Scand A, 95, pp.11~16 (1987)
42. Liu WJ, "p62 links the autophagy pathway and the ubiqutin-proteasome system upon ubiquitinated protein degradation", Cell Mol Biol Lett, 21, pp.29~ (2016)
43. Estep M, "Hepatic sonic hedgehog protein expression measured by computer assisted morphometry significantly correlates with features of non-alcoholic steatohepatitis", BMC Gastroenterol, 19, pp.27~ (2019)
44. Ishak K, "Histological grading and staging of chronic hepatitis", J Hepatol, 22, pp.696~699 (1995)
45. Brunt EM, "Nonalcoholic fatty liver disease(NAFLD)activity score and the histopathologic diagnosis in NAFLD : distinct clinicopathologic meanings", Hepatology, 53, pp.810~820 (2011)
46. Friedman SL, "A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis", Hepatology, 67, pp.1754~1767 (2018)
47. Harrison SA, "Efficacy and safety of aldafermin, an engineered FGF19analog, in a randomized, double-blind, placebo-controlled trial of patients with nonalcoholic steatohepatitis", Gastroenterology, 160, pp.219~231 (2021)
48. Brunt EM, "Misuse of scoring systems", Hepatology, 54, pp.369~370 (2011)
49. Bedossa P, "Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients", Hepatology, 56, pp.1751~1759 (2012)
50. Bedossa P, "Utility and appropriateness of the fatty liver inhibition of progression(FLIP)algorithm and steatosis, activity, and fibrosis(SAF)score in the evaluation of biopsies of nonalcoholic fatty liver disease", Hepatology, 60, pp.565~575 (2014)
51. Leung HH, "Reliability of the nonalcoholic steatohepatitis clinical research network and steatosis activity fibrosis histological scoring systems", J Gastroenterol Hepatol, 37, pp.1131~1138 (2022)
52. Younossi ZM, "Pathologic criteria for nonalcoholic steatohepatitis : interprotocol agreement and ability to predict liverrelated mortality", Hepatology, 53, pp.1874~1882 (2011)
53. Angulo P, "Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease", Gastroenterology, 149, pp.389~397 (2015)
54. Brunt EM, "Improvements in histologic features and diagnosis associated with improvement in fibrosis in nonalcoholic steatohepatitis : results from the nonalcoholic steatohepatitis clinical research network treatment trials", Hepatology, 70, pp.522~531 (2019)
55. Hjelkrem M, "Validation of the non-alcoholic fatty liver disease activity score", Aliment Pharmacol Ther, 34, pp.214~218 (2011)
56. Nascimbeni F, "Clinical validation of the FLIP algorithm and the SAF score in patients with non-alcoholic fatty liver disease", J Hepatol, 72, pp.828~838 (2020)
57. Younossi ZM, "Nonalcoholic steatofibrosis independently predicts mortality in nonalcoholic fatty liver disease", Hepatol Commun, 1, pp.421~428 (2017)
58. Pai RK, "Reliability of histologic assessment for NAFLD and development of an expanded NAFLD activity score", Hepatology, 76, pp.1150~1163 (2022)
59. Brunt EM, "Complexity of ballooned hepatocyte feature recognition : Defining a training atlas for artificial intelligence-based imaging in NAFLD", J Hepatol, 76, pp.1030~1041 (2022)
60. Nakano M, "Histological study on comparison between NASH and ALD", Hepatol Res, 33, pp.110~115 (2005)
61. Kenichi Ikejima, "Nonalcoholic fatty liver disease and alcohol-related liver disease: From clinical aspects to pathophysiological insights", Clinical and Molecular Hepatology, 26(4), pp.728~735 (2020), 대한간학회
62. Kleiner DE, "Histology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in adults and children", Clin Liver Dis, 20, pp.293~312 (2016)
63. Adams LA, "The prevalence of autoantibodies and autoimmune hepatitis in patients with nonalcoholic Fatty liver disease", Am J Gastroenterol, 99, pp.1316~1320 (2004)
64. Vuppalanchi R, "Clinical significance of serum autoantibodies in patients with NAFLD : results from the nonalcoholic steatohepatitis clinical research network", Hepatol Int, 6, pp.379~385 (2012)
65. Cotler SJ, "Prevalence and significance of autoantibodies in patients with nonalcoholic steatohepatitis", J Clin Gastroenterol, 38, pp.801~804 (2004)
66. Vallin M, "Recurrent or de novo nonalcoholic fatty liver disease after liver transplantation : natural history based on liver biopsy analysis", Liver Transpl, 20, pp.1064~1071 (2014)
67. Chan AW, "Steatotic hepatocellular carcinoma : a variant associated with metabolic factors and late tumour relapse", Histopathology, 69, pp.971~984 (2016)
68. 김혜령, "Histopathological Variants of Hepatocellular Carcinomas: an Update According to the 5th Edition of the WHO Classification of Digestive System Tumors", Journal of Liver Cancer, 20(1), pp.17~24 (2020), 대한간암학회[DOI]
69. Salomao M, "The steatohepatitic variant of hepatocellular carcinoma and its association with underlying steatohepatitis", Hum Pathol, 43, pp.737~746 (2012)
70. Yeh MM, "Steatohepatitic variant of hepatocellular carcinoma in the absence of metabolic syndrome or background steatosis : a clinical, pathological, and genetic study", Hum Pathol, 46, pp.1769~1775 (2015)
71. Wong GL, "Artificial intelligence in prediction of non-alcoholic fatty liver disease and fibrosis", J Gastroenterol Hepatol, 36, pp.543~550 (2021)
72. Marti-Aguado D, "Digital pathology enables automated and quantitative assessment of inflammatory activity in patients with chronic liver disease", Biomolecules, 11, pp.1808~ (2021)
73. Popa SL, "Non-alcoholic fatty liver disease: implementing complete automated diagnosis and staging. a systematic review", Diagnostics(Basel), 11, pp.1078~ (2021)
74. Taylor-Weiner A, "A machine learning approach enables quantitative measurement of liver histology and disease monitoring in NASH", Hepatology, 74, pp.133~147 (2021)
75. Forlano R, "High-throughput, machine learningbased quantification of steatosis, inflammation, ballooning, and fibrosis in biopsies from patients with nonalcoholic fatty liver disease", Clin Gastroenterol Hepatol, 18, pp.2081~2090 (2020)
76. Cicchi R, "From molecular structure to tissue architecture : collagen organization probed by SHG microscopy", J Biophotonics, 6, pp.129~142 (2013)
77. Gailhouste L, "Fibrillar collagen scoring by second harmonic microscopy : a new tool in the assessment of liver fibrosis", J Hepatol, 52, pp.398~406 (2010)
78. Bedossa P, "Harmony in liver fibrosis", J Hepatol, 52, pp.313~314 (2010)
79. Ting Soon GS, "Liver biopsy in the quantitative assessment of liver fibrosis in nonalcoholic fatty liver disease", Indian J Pathol Microbiol, 64(Suppl), pp.S104~S111 (2021)
80. 정은선, "Interobserver Agreement on Pathologic Features of Liver Biopsy Tissue in Patients with Nonalcoholic Fatty Liver Disease", Journal of Pathology and Translational Medicine, 50(3), pp.190~196 (2016), 대한병리학회[DOI]
81. Xu S, "qFibrosis : a fully-quantitative innovative method incorporating histological features to facilitate accurate fibrosis scoring in animal model and chronic hepatitis B patients", J Hepatol, 61, pp.260~269 (2014)
82. Sun Y, "Quantitative assessment of liver fibrosis(qFibrosis)reveals precise outcomes in Ishak"stable"patients on anti-HBV therapy", Sci Rep, 8, pp.2989~ (2018)
83. Wang Y, "Dual-photon microscopy-based quantitation of fibrosisrelated parameters(q-FP)to model disease progression in steatohepatitis", Hepatology, 65, pp.1891~1903 (2017)
84. Chang PE, "Second harmonic generation microscopy provides accurate automated staging of liver fibrosis in patients with non-alcoholic fatty liver disease", PLoS One, 13, pp.e0199166~ (2018)
85. Liu F, "Second harmonic generation reveals subtle fibrosis differences in adult and pediatric nonalcoholic fatty liver disease", Am J Clin Pathol, 148, pp.502~512 (2017)
86. Liu F, "qFIBS : an automated technique for quantitative evaluation of fibrosis, inflammation, ballooning, and steatosis in patients with nonalcoholic steatohepatitis", Hepatology, 71, pp.1953~1966 (2020)
87. Leow WQ, "An improved qFibrosis algorithm for precise screening and enrollment into non-alcoholic steatohepatitis(NASH)clinical trials", Diagnostics(Basel), 10, pp.643~ (2020)
88. Thiagarajan P, "Drug development for nonalcoholic fatty liver disease : landscape and challenges", J Clin Exp Hepatol, 9, pp.515~521 (2019)
89. Silvia Sookoian, "Precision medicine in nonalcoholic fatty liver disease: New therapeutic insights from genetics and systems biology", Clinical and Molecular Hepatology, 26(4), pp.461~475 (2020), 대한간학회[DOI]
90. Hannah WN Jr, "Nonalcoholic steatohepatitis and endpoints in clinical trials", Gastroenterol Hepatol(N Y), 12, pp.756~763 (2016)
91. Sanyal AJ, "Endpoints and clinical trial design for nonalcoholic steatohepatitis", Hepatology, 54, pp.344~353 (2011)
92. Rinella ME, "Report on the AASLD", EASL joint workshop on clinical trial endpoints in NAFLD, 2019, pp.71, 823~833
93. Sharma M, "Drugs for Non-alcoholic Steatohepatitis(NASH) : quest for the holy grail", J Clin Transl Hepatol, 9, pp.40~50 (2021)
94. Cheung A, "Defining improvement in nonalcoholic steatohepatitis for treatment trial endpoints : recommendations from the liver forum", Hepatology, 70, pp.1841~1855 (2019)
95. Adams LA, "End-points for drug treatment in NASH", Hepatol Int, 13, pp.253~258 (2019)
96. Hwi Young Kim, "Recent advances in nonalcoholic fatty liver disease metabolomics", Clinical and Molecular Hepatology, 27(4), pp.553~559 (2021), 대한간학회[DOI]

관련 논문AI추천